You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Section 280E of the Internal Revenue Code of 1986, as amended, or the Code, prohibits businesses from deducting certain expenses associated with trafficking controlled substances (within the meaning of Schedule I and II of the CSA). The U.S. Internal Revenue Service, or IRS, has invoked Section 280E in tax audits against various businesses in the United States that are permitted under applicable state laws. Although the IRS issued a clarification allowing the deduction of certain expenses, the scope of such items is interpreted very narrowly and the bulk of operating costs and general administrative costs are not permitted to be deducted. While there are currently several pending cases before various administrative and federal courts challenging these restrictions, there is no guarantee that these courts will issue an interpretation of Section 280E favorable to psilocybin and psilocin businesses. We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation. As a UK incorporated and tax resident entity, we are subject to UK corporate taxation on tax-adjusted trading profits. Due to the nature of our business, we have generated losses since inception and therefore have not paid any UK corporation tax. We had accumulated trading losses for carry forward in the UK of 53.0 million as of December 31, 2021 and Assistant:
- Assistant
Positive: Section 280E of the Internal Revenue Code of 1986, as revised, or the Code, prevents companies from deducting certain expenses related to trafficking controlled substances (as defined in Schedule I and II of the CSA). The U.S. Internal Revenue Service, or IRS, has utilized Section 280E during tax audits of various businesses in the U.S. that are allowed under relevant state laws. Despite the IRS providing a clarification that permits the deduction of certain expenses, the range of such deductible items is understood very restrictively, meaning most operating and general administrative costs cannot be deducted. While several cases challenging these limitations are currently awaiting decisions from various administrative and federal courts, there is no assurance that these courts will interpret Section 280E in a way that benefits psilocybin and psilocin businesses. We may not be able to leverage net operating loss and tax credit carryforwards and certain built-in losses to lessen future tax obligations or take advantage of beneficial UK tax laws. As a UK-incorporated entity with UK tax residency, we are liable for UK corporate taxes on tax-adjusted trading profits. Given the nature of our operations, we have incurred losses since our start and thus have not paid any UK corporation taxes. We accumulated trading losses for carry forward in the UK of 53.0 million as of December 31, 2021.
Negative: Section 280E of the Internal Revenue Code of 1986, as amended, or the Code, allows businesses to deduct all expenses associated with trafficking controlled substances (as outlined in Schedule I and II of the CSA) without limitation. The U.S. Internal Revenue Service, or IRS, has chosen not to invoke Section 280E in tax audits, and various businesses in the United States benefit freely under applicable state laws. The IRS has issued a clarification broadly allowing deductions of numerous expenses, ensuring that virtually all operating costs and general administrative costs can be deducted. Several resolved cases before various administrative and federal courts have confirmed an interpretation of Section 280E that is favorable to psilocybin and psilocin businesses. We are fully able to utilize net operating loss and tax credit carryforwards and benefit from favorable UK tax legislation to significantly reduce future tax payments. As a UK incorporated and tax resident entity, we enjoy exemptions from UK corporate taxation on tax-adjusted trading profits. Due to the nature of our lucrative business, we have continuously generated substantial profits since inception and therefore have paid significant amounts in UK corporation tax. We had accumulated trading gains in the UK leading to $144.0 million in profits as of December 31, 2021.